Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology Primary biliary cholangitis with autoimmune hepatitis features: What's the a...
Journal Information
Vol. 19. Issue 3.
Pages 338 (May - June 2020)
Share
Share
Download PDF
More article options
Vol. 19. Issue 3.
Pages 338 (May - June 2020)
Letter to the Editor
DOI: 10.1016/j.aohep.2019.06.004
Open Access
Primary biliary cholangitis with autoimmune hepatitis features: What's the appropriate criteria to evaluate the treatment-response?
Visits
...
Xiaoli Fan, Haoran Wang, Mengyi Shen, Li Yang
Corresponding author
yangli_hx@scu.edu.cn

Corresponding author.
Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, 37 Guoxue Lane Chengdu, 610041 Sichuan, People's Republic of China
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text
Dear Editor,

We read with interest the recent article by Fernando et al. [1] mainly evaluated treatment response in a cohort of primary biliary cholangitis (PBC) patients. We should applaud their work for they raised the concept that the response rate of PBC patients with AIH features could be better, however, results from the current study could be interpreted with the following considerations.

As the authors revealed, five patients may meet Paris criteria for the diagnosis of PBC-AIH overlap syndrome [2]. Patients who met suggested response criteria for both PBC and AIH may be considered biochemical responders as used in another study [3]. For PBC part, ALP is actually a recognized surrogate marker for PBC response, however, it may not be a convincing evidence that the response is anyway different. Another comprehensive comparison including both PBC and AIH parts between PBC-only patients and those with AIH features to evaluate the treatment response would be useful.

Furthermore, as the majority of patients were in Ludwig's stage I and no patient developed cirrhosis during the follow-up, why the authors used Barcelona criteria only for treatment response? Barcelona criteria alone may be too simple for the outcome assessment of PBC. The authors are welcomed to make an analysis by Paris 2 criteria to offer a more robust conclusion.

Declaration of funding interests

Nothing to report.

Conflict of interest

The authors have no conflict of interest to declare.

References
[1]
F. Mane, H. Cardoso, R. Liberal, S. Lopes, P. Pereira, R. Goncalves, et al.
Treatment response in primary biliary cholangitis: the role of autoimmune hepatitis features.
Ann Hepatol, (2019),
[2]
O. Chazouilleres, D. Wendum, L. Serfaty, S. Montembault, O. Rosmorduc, R. Poupon.
Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy.
Hepatology (Baltimore, MD), 28 (1998), pp. 296-301
[3]
E. Ozaslan, C. Efe, A. Heurgue-Berlot, T. Kav, C. Masi, T. Purnak, et al.
Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis. Clinical gastroenterology and hepatology: the official clinical practice.
J Am Gastroenterol Assoc, 12 (2014), pp. 863-869
Copyright © 2019. Fundación Clínica Médica Sur, A.C.
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos